It remains obscure in myxofibrosarcoma about the basis of tumorigenesis, progression, and metastasis. Chromosome 7 gains are common in some sarcomas, including myxofibrosarcoma, whereas the specific oncogenes are yet to be characterized. We performed an integrative study of MET gene at 7q31.2 to elucidate its implication in myxofibrosarcoma. Focused on candidate oncogenes on chromosome 7, 385K array comparative genomic hybridization was used to profile DNA copy number alterations of 12 samples. MET transcript was successfully quantified by real-time RT-PCR for 16 laser-microdissected tumors and two myxofibrosarcoma cell lines (NMFH-1, OH931). MET immunoexpression was assessable in 86 primary localized tumors with followup. To analyze endogenous MET expression and activation, NMFH-1 and OH931 cells, both with wild-type MET gene, were subjected to Western blotting and hepatocyte growth factor-treated NMFH-1 cells were evaluated for the kinetics of MET tyrosine phosphorylation. Non-random large-scale gains on 7q were detected in five cases, delineating three recurrent amplicons, 7q21.11-7q21.3, 7q22.1-22.3, and 7q31.1-7q32.3, in which the locus of MET displayed increased copy number, among others. MET mRNA was upregulated in OH931, NMFH-1, and nine tumors (56%), whereas neither gene dosage nor mRNA expression of MET was associated with clinicopathological factors. In contrast, MET protein overexpression, present in 67% of cases, was highly related to deep location (P ¼ 0.004), higher grades (P ¼ 0.001), and more advanced stages (Po0.001). Importantly, MET overexpression independently portended inferior metastasis-free survival (P ¼ 0.004) and overall survival (P ¼ 0.0221). Expressing activating phospho-MET at Tyr 1234 /Tyr 1235 , OH931 cells had more abundant total MET than NMFH-1 cells, whereas the latter became promptly phosphorylated on stimulation of
Myxofibrosarcoma is a common sarcoma characterized histologically by multinodular growth of spindle to polygonal sarcoma cells within variably myxoid stroma containing long curvilinear vessels. 1 Clinically, increased tumor grading and staging are frequently seen in myxofibrosarcomas after relentless local recurrences, which may eventually lead to metastatic diseases. [1] [2] [3] Especially for those at the low-grade end, it seems challenging to predict acquisition of invasive and metastatic properties for individual cases by histological evaluation. [1] [2] [3] Furthermore, metastatic myxofibrosarcomas are often refractory to current treatment strategies and constitute the primary cause of sarcoma-related death. 1, 3, 4 To develop novel therapeutic interventions, it is highly desirable to elucidate the molecular determinants correlated with tumor invasion and metastatic spread in myxofibrosarcoma progression.
Somatic alterations in cellular DNA underlie most human cancers. Gains of gene copy number drive expression of oncogenes, whereas decreased gene dosage by hemizygous and/or homozygous deletion results in inactivation of tumor suppressor genes. 5 The prospect of genomic profiling with derived targeted therapies is now prompting increasing efforts to characterize cancer genomes. 5 There is mounting evidence that regional gains and/or high-level amplifications on chromosomal arm 7q are recurrently found in various types of bone and soft tissue sarcomas, [6] [7] [8] [9] [10] [11] [12] including myxofibrosarcomas. 8 However, as for myxofibrosarcomas, the pathogenetically relevant target oncogenes on 7q and their prognostic implications remain largely unknown.
Compared with conventional comparative genomic hybridization (CGH), array CGH (aCGH) is promising to narrow down imbalanced chromosomal regions. 5, 8, 13, 14 In this series, we applied ultrahigh-resolution tiling-path aCGH to pinpoint breakpoints of DNA copy number alterations (CNAs) in chromosome 7 for 12 myxofibrosarcomas, so as to identify candidate oncogenes implicating its tumorigenesis. Special attention was given to chromosomal segments harboring the established oncogenes, such as hepatocyte growth factor (HGF) at 7q21 and MET at 7q31. Acting as a multi-functional cytokine on cells, HGF is typically secreted by mesenchymal cells as a single-chain propeptide that requires proteolytic cleavage to generate an active a/b heterodimer. [15] [16] [17] MET encodes the 170-kd precursor of a transmembrane receptor tyrosine kinase, which constitutes the only known high-affinity receptor of HGF after cleavage into the 50-kd a subunit and 140-kd b subunit and linkage by disulfide bonds. [15] [16] [17] In human cancers, aberrant c-Met signaling has been shown to result from diverse HGF liganddependent and -independent mechanisms, including activating mutation, autocrine/paracrine HGF stimulation, and overexpression with or without gene amplification. [15] [16] [17] [18] [19] A subset of common carcinomas is known to harbor amplified MET gene (eg gastric cancers, 10-20%; lung cancers, 7%; metastatic colorectal cancers, 9-18%), 15, 17, 20 which is therapeutically relevant in prediction of response to selective MET tyrosine kinase inhibitors. 20 Despite more frequent MET overexpression in higher-grade lesions, MET gene amplification was not found by Southern blots in 35 various soft tissue tumors tested, 21 unlike that observed in 7,12-dimethylbenz(a)anthracene-induced rat sarcomas. 21, 22 Given its crucial function in tumor biological function, MET has emerged as a promising target for cancer therapy. 15, 17, 23 In this context, we conducted by far the first systematic study to elucidate the underlying molecular aberrations and mRNA abundance of MET in selected fresh tumor samples and its protein expression and prognostic significance in 86 archival primary localized myxofibrosarcomas. Furthermore, the endogenous expression level and activation status of MET were examined by Western blotting for two myxofibrosarcoma cell lines (OH931 and NMFH-1), with the lower MET-expressing NMFH-1 cells also evaluated for the kinetic alteration of MET phosphorylating activation in response to exogenous HGF treatment.
Materials and methods

Cell Culture
The OH931 and NMFH-1 myxofibrosarcoma cell lines were established and kindly provided by Dr Bridge 24 and Dr Ogose, 25 respectively. Both sarcoma cell lines were grown in RPMI 1640 medium supplemented with fetal bovine serum (20% for OH931; 10% for NMFH-1), 1% penicillin/streptomycin, and 1% L-glutamine. In addition, 1% HEPES was also added to the RPMI1640 medium to culture OH931 cells. The CCD966SK dermal fibroblast cell line was purchased from the repository of Taiwan BCRC and cultured in minimum essential medium (Eagle) in Earle's BSS containing 10% of heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, and 1% of non-essential amino acids.
Sequencing of MET Gene
Both OH931 and NMFH-1 myxofibrosarcoma cells were extracted for genomic DNA to perform extensive sequencing of MET gene, covering the extracellular semaphorin domain, IPT repeats, juxtamembrane domain, and tyrosine kinase domain, based on the earlier reported mutation frequency and methodologies with minor modifications. 16 The sequences of primer pairs will be provided on request.
Patients and Tumor Materials
The criteria of histopathological diagnosis and assessment for various parameters were elaborated in our earlier publications. 3, 4, 26 Histological grading and staging were classified according to updated French Federation of Cancer Centers (FNCLCC) scheme 27 and the 6th edition of American Joint Committee on Cancer (AJCC) system, respectively. Retrospective clinical data collection and tissue procurement were in accordance with the local guidelines of research ethics (97-1110A3). For genomic profiling, aCGH was used to evaluate somatic CNAs in 12 fresh tumor specimens (six primary, six recurrent). To evaluate the reliability of CNAs obtained from aCGH profiling, 17 selected fresh specimens of myxofibrosarcomas were subjected to laser capture microdissection (LCM) for quantification of MET mRNA expression by real-time reverse-transcription PCR (RT-PCR). To perform MET immunostain, we retrieved representative paraffin-embedded blocks of primary localized myxofibrosarcomas of 86 patients from the archives of three tertiary medical centers. In the absence of preoperative neoadjuvant radiation or chemotherapy, these 86 patients, all with available clinical follow-up, received surgical excision with curative intent between 1986 and 2005. Postoperative adjuvant radiotherapy (n ¼ 21) and/or chemotherapy (n ¼ 7) were randomly given in a minor subset of high-grade or recurrent cases without consistent guidelines. Details on clinicopathological characteristics of cohorts used in aCGH analysis and immunoexpression were summarized in Tables 1 and 2. DNA Preparation, Hybridization, and Data Analysis of aCGH On the basis of H&E sections, regions suitable for DNA extraction were dissected from 12 fresh specimens after trimming necrotic and fibrous areas to assure higher than 80% of tumor content. The reference DNAs were obtained from adjacent normal tissues available in five cases and from normal lymphocytes of gender-matched donors in the remaining seven cases. For each case, 1 mg of total genomic DNA at a concentration of 500 ng/ml was extracted from fresh tissue by using 'recoverall DNA Purification kits' (Ambion, Austin, TX, USA) for hybridization against oligonucleotide microarrays. To ensure DNA integrity, each sample should have an A 260/280 ratio of 1.7-2.0 and no sign of degradation, as evaluated by gel electrophoresis. Each tiling-path whole genomic microarray had 385K oligonucleotide probes with a median spacing of 6 kb and variable length to achieve a melting temperature of 761C (NimbleGen Systems, Madison, WI, USA). The procedures of DNA labeling, hybridization, normalization of oligonucleotide arrays, window averaging of contained probes, and data acquisition were carried out by the facility of manufacturer as earlier reported. 13 Briefly, genomic DNAs of tumor and reference samples were sonicated to a size range of 500-2000 bp before labeling by random priming with fluorescent Cy3 and Cy5, respectively. After combining the data of signal intensity with information of the genomic coordinates, the Cy3 and Cy5 signal intensities are MET overexpression in myxofibrosarcoma J-C Lee et al normalized to one another using Qspline normalization, a robust non-linear normalized method for two-color experiments. The circular binary segmentation algorithm proposed by Olshen et al, 28 was used for segmentation of the averaged log 2 ratio data. Each segment was then assigned a log 2 ratio that was the median of 10 contained probes, and the data were centered by the tallest mode in the distribution of the segmented values. To finely delineate the breakpoints of whole array probes, we defined gains and losses as log 2 ratios of Z þ 0.20 or rÀ0.20, respectively.
Real-Time RT-PCR to Measure MET mRNA Expression Level in Fresh Samples and Cell Lines of Myxofibrosarcoma
To circumvent the contamination of the surrounding non-neoplastic cells, we adopted LCM technology to , total RNA was reverse transcribed in a final volume of 40 ml with the following conditions: 2 ml of total RNA from LCM-isolated cells of each tissue sample (or 2 mg of total RNA from each cell line), 0.5 mmol/l dNTPs, 25 U of RNase inhibitor, 16 ml of RNA eluant, and 4 ml of random primers. The reactions were performed at 421C for 60 min, followed by inactivation of the enzyme at 701C for 15 min. Real-time PCR assays to quantify the expression levels of MET transcript were performed using the LightCycler instrument 2.0 (Roche molecular diagnostics, Mannheim, Germany). The intron-spanning primers and LON probes for cDNAs of target and housekeeping (POLR2A, a.k.a. RPII) genes were ordered from Universal Probelibrary and their corresponding nucleotide sequences were MET: sense, agtgggaattctagacacatttca, UPL probe no. 31 (tggtggaa), and antisense, cattcaagaatactgtttgacacactt; POLR2A: sense, gcatcatgaacagcgatgag, UPL probe no. 69 (ggaggaag), and antisense, tcatccatcttgtccaccac. Amplification was conducted in duplicate for each reaction for fresh specimens and in triplicate for cell lines with LightCycler TaqMan MasterMix, using 2 ml of cDNAs (or 1000-fold diluted for cell line samples), 100 nmol/l of the probes, and 200 nmol/l of the primers in a final 20 ml of reaction mixture. After 2 min incubation at 401C to allow for uracil N-glycosylase cleavage, Taq DNA polymerase was activated by incubation for 10 min at 951C. Each reaction of the 45 PCR cycles consisted of 10 s of denaturation at 951C and hybridization of the probe and primers for 30 s at 601C. After normalization to POLR2A, the relative expression fold of MET transcript was then given by 2 ÀDDCp , where DDC T ¼ DC T ( Sarcoma cells )ÀDC T ( CCD966SK ) or ¼ DC T ( tumor specimens )ÀDC T ( normal fibromuscular tissue ), and DC T represented the C T of MET subtracted from the C T of POLR2A. Only samples with C T value o33 for POLR2A were considered to have acceptable RNA quality and included in the analyses.
Immunohistochemistry
For each of the 86 cases tested, MET immunohistochemistry was performed on one 4-mm-thick, formalin-fixed tissue section from a representative block. The tissue sections were then deparaffinized in xylene, rehydrated in graded alcohols, quenched with 3% H 2 O 2 , microwave heated for antigen retrieval in 0.01 M citrate buffer at pH 6.0 for 15 min, and incubated in 10% normal goat serum for 30 min to block non-specific immunoreactivity. Afterwards, the tissue sections were incubated at 41C overnight with a primary antibody against total MET (1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA), washed with PBS, and detected by using the streptavidin-biotin immunoperoxidase method. Diaminobenzidine was used as the chromogen and Mayer's hematoxylin was as the counterstain. One of the authors (JCL), blind to clinicopathological data, independently evaluated the slides. The labeling intensity of MET was classified as negative, weak, moderate, and strong. MET reactivity was predominantly seen in the cytoplasm, with only few cases also exhibiting distinct membranous staining. Therefore, the percentage of tumor cells with moderate or strong cytoplasmic immunoreactivity, with or without membranous staining, was recorded as expression index in 5% increment. After testing a series of cutoff values, MET protein was construed as overexpressed when the expression index was Z30% of tumor cells.
Western Blotting Assays to Assess the Endogenous Protein Expression and Activation of MET in Myxofibrosarcoma Cell Lines
Equal amounts of total protein (25 mg) extracted from OH931, NMFH-1, and CCD966SK cell lines were separated on 4-12% gradient SDS-PAGE gel NuPAGE (Invitrogen, Carlsbad, CA, USA), transferred to PVDF membranes (Amersham Biosciences, Buckinghamshire, UK), and then blocked with 5% skimmed milk in TBST buffer at room temperature for 1 h. Afterwards, the membranes were probed with antibodies at 41C overnight against total MET (1:200, 3D4; Zymed, South San Francisco, CA, USA), phosphorylated MET at the tyrosine residues 1234/1235 (Tyr 1234 /Tyr 1235 , 1:200, D26; Cell Signaling Technology, Beverly, MA, USA), and GAPDH (1:10000, MAB347, Chemicon) for a loading control and then incubated with the secondary antibody at room temperature for 1.5 h. Enhanced chemiluminescence reagents (Amersham Biosciences) were used to visualize the targeted proteins, which were then semi-quantitatively measured by densitometry. The endogenous expression level and activation status of MET in OH931 and NMFH-1 cells were compared with those of CCD966SK fibroblasts.
Evaluation of the Kinetic Alteration of Tyrosine
Phosphorylation in Response to Exogenous HGF Stimulation in NMFH-1 Cells To evaluate the tyrosine phosphorylation of MET, NMFH-1 cells grown in 6-cm dishes were serum starved overnight, cultured with fresh minimal essential medium containing non-essential amino acids, and treated with either 50 ng/ml recombinant human HGF (H9661, Sigma, St Louis, MO, USA) or serum-free medium alone for indicated time intervals. For Western blotting assay, total protein (40 mg each) was extracted from NMFH-1 cells harvested from various batches with or without HGF stimulation at different time intervals, with b-actin (1:3000, MAB1501, Chemicon) serving as the loading control.
Follow-Up and Statistical Analyses
Statistical analyses were performed using SPSS 14 software package. Associations and comparisons of MET mRNA expression or immunoexpression with various clinicopathological parameters were evaluated by Student's t-test, one-way ANOVA, Kruskal-Wallis, or Pearson's correlation coefficient test as appropriate. In the 86 patients tested for MET immunoexpression, the observation intervals of follow-up ranged from 2 to 229 months with the median duration of 44.8 months as of January 2008, forming the basis for prognostic analysis. The end points evaluated for survival analyses were overall survival (OS) and metastasis-free survival (MeFS). The cutoffs of various clinicopathological parameters for prognostication were described earlier. 3, 4, 26 In univariate survival analysis, KaplanMeier curves were plotted for each variable and the difference between groups compared by the log-rank test. In Cox multivariate regression model, all significant parameters identified at the univariate level were entered to compare the independent prognostic impact. Student's t-test was used to analyze the results of real-time quantitative RT-PCR for cell line samples. For all analyses, two-sided tests of significance were used with Po0.05 considered significant.
Results
Genomic Profiling of Chromosome 7 by Ultrahigh-Resolution aCGH
Chromosomal imbalances of varying size were detected in all 12 samples subjected to aCGH profiling. Examples of aCGH profiles are shown in Figure 1 . Although large-scale chromosomal gains were only seen in two (MFS64, MFS96b) cases on 7p and five cases on 7q (MFS19b, MFS64, MFS84b, MFS96b, MFS99b), non-contiguous segmental copy number gains interspersed by small interstitial regions of no alteration were frequently detected on at least one of both arms. The later finding might be attributed to the higher resolution of current aCGH platform to localize exact breakpoints. Besides, there was no apparent correlation of CNAs of chromosome 7 with the tumor grading, staging, or primary vs recurrent status of myxofibrosarcoma. To unravel causal genes showing copy number-driven deregulated expression, we filtered the imbalanced chromosomal regions with non-random alterations at the identical DNA segments in at least 40% of samples. Accordingly, recurrent regions of gain and/or amplification were mapped to 7p14.3 and 7p14.1 on the p arm and 7q21.11-7q21.3, 7q22.1-22.3, and 7q31.1-7q32.3 on the q arm. Among the three amplicons on the q arm, we found that nine, three, and six loci of DNA gains in the chromosomal regions 7q21.11-7q21.3, 7q22. 35 and SND1 (7q32.1). 36 However, complete genomic DNA gains at the probes spanning HGF were only observed in three cases ( Figure  1 ). On the other hand, DNA losses tended to be small focal changes and recurrently mapped to 7p22, 7p12.3, and 7q11.23 in which three earlier reported candidate tumor suppressor genes, that is MAD1L1 (7p22.3), 37 TNS3 (7p12.3), 38 and CLDN4 (7q11.23), 39 were located. 
MET Transcript Was Frequently Upregulated in Myxofibrosarcoma Specimens but not Associated with Clinicopathological Factors
Next, we addressed whether the mRNA expression of MET gene was upregulated in at least a subset of myxofibrosarcoma specimens as inferred from the aCGH findings and whether there was association between the expression level of MET transcript and clinicopathological factors. Real-time RT-PCR quantification could be successfully determined with sufficient RNA yields in LCM-isolated pure tumor cells (Figure 2a ) of 16 fresh myxofibrosarcoma samples, including four grade 1, seven grade 2, and five grade 3 cases. As compared with the normal adjacent fibromuscular tissues, we found that 9 out of 16 cases tested showed more than threefold higher expression of MET transcripts, suggesting their frequent upregulation in human myxofibrosarcomas. However, there was no significant difference among myxofibrosarcoma specimens regarding various clinicopathological characters, including grading (Figure 2b) , staging, and primary vs recurrent status, which was generally in keeping with the aCGH findings.
Expression and Activation of Endogenous MET Kinase in Myxofibrosarcoma Cell Lines
Given activating MET mutations identified in few cancer types, [15] [16] [17] 23 we extensively sequenced the genomic DNAs of OH931 and NMFH-1 myxofibrosarcoma cell lines and found wild-type MET gene in both (data not shown). Real-time RT-PCR quantification in triplicate measurements (Figure 3a) showed that the expression levels of MET mRNA were significantly higher in two myxofibrosarcoma cell lines than in the non-transformed CCD966SK fibroblasts (Po0.001). In addition, OH931 myxofibrosarcoma cells also had significantly more abundant MET mRNA when compared with NMFH-1 (Po0.001). It has become explicit that the Tyr 1234 /Tyr 1235 residues of MET kinase must be first activated by phosphorylation to relay MET-mediated signaling, a prerequisite critical for tumor growth and progression. 15, 19, 23, 40 We, therefore, further compared the endogenous expression and activation status of MET protein in myxofibrosarcoma cells vs CCD966SK fibroblasts. By Western blotting, OH931 myxofibrosarcoma cells showed high endogenous expression of total MET, whereas it was comparatively lower in abundance in NMFH-1 cells and barely detectable in CCD966SK fibroblasts ( Figure 3b, row 2) . However, endogenous phosphorylation of MET at Tyr 1234 /Tyr 1235 was only detected in OH931 myxofibrosarcoma cells (Figure 3b, row 1) .
Tyrosine Phosphorylation of MET in Response to Recombinant HGF Stimulation in NMFH-1 Myxofibrosarcoma Cells
As NMFH-1 cells showed relatively lower endogenous expression of MET protein without apparent phosphorylating activation, we further examined its kinetics of tyrosine phosphorylation of MET in response to exogenous HGF ligand. As shown in Figure 3c , phosphorylation of Tyr 1234 /Tyr 1235 was observed at 5 min after HGF treatment and lasted until 10 min. Afterwards, expression of phospho-MET Tyr1234/Tyr1235 started to diminish. The total amount of MET protein was decreased at 60 min after HGF treatment, probably because of the degradation by proteasome after internalization.
Correlations of MET Immunoexpression with Clinicopathological Factors in Primary Myxofibrosarcomas
MET protein in primary myxofibrosarcomas was successfully scored for 86 cases (Table 2) cases were AJCC stage I, stage II, and stage III, respectively. However, the tumor staging of three remote cases could not be determined due to the lack of data of tumor size. As shown in Table 2 and Figures 4d-f , MET was overexpressed in 58 cases (67%) with an expression index Z30%, whereas MET expression in the remaining 28 cases was either absent (n ¼ 10) or low (n ¼ 18, expression index Z5% but o30%). MET immunolabeling was significantly higher in expression index in those myxofibrosarcomas that were deep seated (P ¼ 0.004), classified as FNCLCC grade 2 or grade 3 (P ¼ 0.001), and more advanced in AJCC staging (Po0.001). In addition, MET expression index was positively related to increased tumor size (P ¼ 0.003), mitotic rate (P ¼ 0.008), and percentage of tumor necrotic area (Po0.001), but inversely associated with the proportion of myxoid component (Po0.001). However, we could not substantiate the associations of MET overexpression with age, gender, and tumor location.
Survival Analyses
At last follow-up, 15 patients died of the tumors, 7 died of other causes, 14 were alive with tumors, and 50 were alive without evidence of tumor. Correlations of patient survivals with immunohistochemical and various clinicopathological parameters at the univariate level are shown in Table 3 and Figure 5 . The cumulative 5-year rates of OS and MeFS were 62.7 and 50.1%, respectively, in patients with primary localized myxofibrosarcomas. In agreement with our and others' earlier reports, 1, 2, 4 several clinicopathological factors significantly correlated with adverse outcomes with respect to both end points, including the deep locations (OS, P ¼ 0.0321; MeFS, P ¼ 0.0162), high mitotic count (OS, Po0.0001; MeFS, Po0.0001), higher histological grades (OS, P ¼ 0.0437; MeFS, P ¼ 0.0030), and AJCC stage III (OS, P ¼ 0.0354; MeFS, P ¼ 0.0056). However, older age (P ¼ 0.0333), larger tumor size (P ¼ 0.0124), and remarkable tumor necrosis (P ¼ 0.0010) were only significantly related to worse MeFS. More importantly, MET overexpression was found not only significantly associated with inferior OS (P ¼ 0.0032, Figure 5a ), but also strongly predictive of worse MeFS (P ¼ 0.0007, Figure 5b ).
In multivariate analysis (Table 4) , MET overexpression remained as an independent adverse prognosticator for both OS (P ¼ 0.0221) and MeFS (P ¼ 0.0040), along with high mitotic count (Po0.0001 for both OS and MeFS). In addition, MET overexpression also identified patients at more than six-and ninefold higher risks of worse OS and MeFS rates, respectively. However, an older age (P ¼ 0.0003) at presentation was independently predictive of worse MeFS alone. Other significant factors at the univariate level lost their statistical significance, including histological grading and tumor staging.
Discussion
The management of myxofibrosarcoma is complicated by the lack of good prognosticators to accurately determine tumor invasion and metastatic spread. However, it is perceived that increased clinical aggressiveness of myxofibrosarcoma is accompanied by phenotypic change from predominantly loose myxoid to more cellular solid histology, [1] [2] [3] which provides a unique model of exploring based aCGH, 8 which comprised only 1440 target DNA clones to cover the whole genome. Despite being one of the most common CNAs (4/8, 50%) reported by Ohguri et al, gains at 7p21.1-p22.1 were present in a minor proportion of our cases, not fulfilling our threshold to define non-random aberrations in aCGH profiling. In this study, three amplicon cores were mapped to 7q21.11-7q21.3, 7q22.1-q22.3, and 7q31.1-7q32.3, respectively, which harbored established oncogenes on the q arm, including CDK6 (7q21.2) and MET (7q31.2). However, the boundaries of these recurrent CNAs did not overlap 7q33-q35, the minimal common region of DNA gains on 7q in the series of Ohguri et al. 8 By using RNA extracted from LCM-isolated tumor cells for validation, 56% of 16 myxofibrosarcoma specimens showed apparently upregulated MET transcript by real-time RT-PCR. This finding suggested that MET should represent a bona fide oncogene located within regions of chromosomal gain on 7q in myxofibrosarcoma, rather than a co-amplified 'passenger' unrelated to tumorigenesis. Although histological grade and tumor stage of myxofibrosarcoma were identified as univariate adverse prognosticators, neither of these was associated with increased copy number gains or mRNA expression levels of MET oncogene. Intriguingly, we found that immunoexpression of MET protein was significantly higher in myxofibrosarcomas with unfavorable features, such as deeper location, higher grades, more advanced stages, and so on. Regarding the correlations with clinicopathological factors, we consider that the relatively fewer case numbers used in aCGH profiling and real-time RT-PCR quantification should not entirely account for the discrepancy in implications between MET protein expression and its gene dosage and mRNA abundance. This argument was partly in keeping with the findings of a karyotypic study of 32 myxofibrosarcomas, showing that chromosomal aberrations were not restricted to higher-grade myxofibrosarcomas, but could also be observed in low-grade tumors, albeit less frequently. 41 In many tumors, MET protein is actually expressed at levels much higher than in the normal counterpart. 16, 17 However, it has become more explicit that the upregulatory mechanisms of MET protein expression appear more complex than earlier thought and that most mechanisms identified thus far, such activation of other oncogenes and transcription factors, inactivation of p53 tumor suppressor, hypoxia, and so on, are known to increase MET gene transcription. [15] [16] [17] 21, 23, [42] [43] [44] More recently, several small non-coding microRNAs, including miR-34b, miR-34c, miR-199a*, miRNA-1, and miRNA-206, have been proved to upregulate MET protein expression in a variety of cancers by either targeting MET mRNA for degradation or repressing its translation post-transcriptionally. 43, [45] [46] [47] These microRNAs may constitute a novel and critical mechanistic basis to modulate MET expression in tumor cells. Through binding of activated HGF to its extracellular domain, MET undergoes oligomerization with subsequent phosphorylation of multiple tyrosine residues at the intracellular domains of the b subunit, thereby modulating its internalization, catalytic activity, and docking of adaptor proteins. 15, 18, 19, 21, 23, 40, 44, 48 The interaction between HGF and MET has vital functions in orchestrating the 'invasive growth program' acquired in cells involving various physiological processes, such as embryonic organ morphogenesis and tissue repair. 15, 18, 19, 23, 41, 48 Besides mitogenic and antiapoptotic activities common to many growth factor receptors, heightened MET activation can stimulate cell-cell detachment, migration, invasiveness, and angiogenesis. 15, 18, 19, 23, 40, 48 However, the biological and prognostic implications of MET overexpression in human mesenchymal malignancies vary among series and may be tumor type-dependent. 42 ,44,49-51 MET ovexpression is present in a high percentage of human rhabdomyosarcomas and osteosarcomas. 42, 44, 49 In rhabdomyosarcomas, MET overexpression not only correlates with alveolar histology and advanced group, but also has an important function in the dissemination to bone marrow, 49 whereas only expression of HGF enhances the resistance to radiochemotherapy. 48 Recently, the tumorigenic property of MET oncogene in osteosarcomas was further reinforced by a study showing that MET overexpression can drive the transformation of human primary cultured osteoblasts into bone-forming sarcoma cells, both in vitro and in vivo.
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In synovial sarcomas, MET is expressed in approximately one-third of cases and co-expression of both MET and HGF, instead of MET expression alone, correlates with adverse outcomes. 51 Conversely, MET overexpression was frequently found in skull base chordomas, but significantly predictive of favorable prognosis. 50 In primary myxofibrosarcomas, we have identified for the first time that MET overexpression was independently predictive of shorter OS and MeFS as well as being associated with tumor size and mitotic rate. Our findings and the reported discrepancies in the implications of MET expression among various sarcoma types indicated its pleiotropic functions in tumor development, progression, and dissemination.
It has become clarified that activating mutations constitutively elicit MET signaling only in few tumor types, such as papillary renal cell carcinomas and gastric carcinomas. 15, 17, 23 We performed direct sequencing for OH931 and NMFH-1 myxofibrosarcoma cells and found wild-type MET oncogene in both cell lines. Actually, MET receptor tyrosine kinase in most cancers is more frequently activated by transcriptionally upregulated or amplificationdriven protein overexpression. 15, 17, 23, 43 In this study, NMFH-1 myxofibrosarcoma cells, with lower endogenous MET expression, were responsive to treatment of recombinant HGF ligand by showing phosphorylation at Tyr 1234 /Tyr 1235 , two tyrosine residues essential for HGF-dependent activation of MET kinase. 40 Although the activating phosphorylation induced by exogenous HFG ligand only lasted transiently, this finding suggested the possibility of an ectopic autocrine or paracrine loop in myxofibrosarcomas that mediates the HGF-MET signaling pathway. This scenario had been earlier exemplified in osteosarcomas, rhabdomyosarcomas, gliomas, and so on, when the tumors or surrounding microenvironments aberrantly express MET receptor or its HGF ligand. 18, 19, 48 In conclusion, our work highlights the value of genomic profiling with ultrahigh-resolution aCGH. In myxofibrosarcomas, it shows recurrent regions of gain harboring oncogenes on 7q and the likelihood of an increased MET gene dosage in the induction of mRNA expression. Immunohistochemically, approximately two-thirds of primary localized tumors display MET protein overexpression, which correlates with adverse clinicopathological factors and independently portends worse MeFS and OS. Our 
